Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × HER2 Positive Breast Cancer × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Ovarian Neoplasms 4 Neoplasms 3 Inflammatory Breast Neoplasms 3 HER2-positive Breast Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive Early Breast Cancer 1 HER2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1

Interventions

pertuzumab 1 Trastuzumab 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01904903 2022-05-10

SAFE-HEaRt

Medstar Health Research Institute

Phase 2 Completed

31 enrolled 12 charts

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡